The case for & against
Bull & Bear analysis
Bearish
Stereotaxis, Inc. (NYSE: STXS) is a pioneering player in the medical device sector, focusing on robotic systems designed for electrophysiology and minimally invasive surgeries. Leveraging advanced technologies, Stereotaxis aims to elevate clinical performance through innovative catheter solutions. The company is transitioning from traditional products towards a disposable revenue model, emphasizing growth and efficiency in treating complex cardiac conditions. With a clear trajectory towards capturing a larger market segment, Stereotaxis is well-positioned to benefit from the rising demand for minimally invasive surgical technologies.
Bull says
- ↑Regulatory OK for MAGIC catheter and Genesis X fuels disposables growth.
- ↑Management targets quarterly revenues above $10M in Q3–Q4 2026.
- ↑~30% of EU accounts have adopted MAGIC catheter early.
- ↑Disposables model aims to lift per-procedure revenue from $1K to ~$5K.
- ↑$14.6M cash, zero debt supports ongoing product transition.
- ↑Positive momentum factor reflects recent uptick in stock performance.
Bear says
- ↓Q1 2026 revenue dropped to $6.3M from $7.5M year-over-year.
- ↓Q1 operating loss of $6M and negative $3.5M free cash flow.
- ↓Low profitability and negative earnings yield hinder sustainable returns.
- ↓Transition from J&J ecosystem fuels revenue volatility and execution risk.
- ↓Competition from Medtronic and Boston Scientific may slow adoption.
- ↓High stock volatility deters conservative investors amid execution uncertainties.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-03-2026neutral
Transcript signals
Bull points
- Revenue for the first quarter of 2025 totaled $7.5 million, growth of 9% from $6.9 million in the prior year first quarter.
- recurring revenue was $5.5 million compared to $4.3 million in the prior year first quarter, reflecting primary contributions from last year's acquisition of APT technology.
- we expect recurring revenue margins to get back to a normal level by this year's third quarter.
Bear points
- The increase in operating expenses reflects the addition of APT operating expenses following the acquisition.
- Operating loss and net loss in the first quarter of 2025 were $5.9 million and $5.8 million compared with $4.7 million and $4.5 million in the previous year.
- Adjusted operating loss and adjusted net loss for the quarter excluding non-cash charges were $2.7 million and $2.6 million compared with $2.2 million and $1.9 million in the previous year.
Read full transcript analysis ›